Skip to content
zynerba logo
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZygelTM
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q

Zynerba Press Releases

22 Mar 18 Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

14 Mar 18 Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

12 Mar 18 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights

5 Mar 18 Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing

3 Jan 18 Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

3 Dec 17 Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)

21 Nov 17 Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)

14 Nov 17 Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

7 Nov 17 Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences

28 Sep 17 Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome

Page 14 of 20 | « First‹ Previous10 11 12 13 14 15 16 17 18 Next ›Last »

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Cookie Notice
    • Accessibility Statement
    • Contact Us

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505